Trulicity Bone Health and Density Impact: What the Evidence Shows

Does Dulaglutide Affect Bone Mineral Density?

Current evidence indicates that dulaglutide does not meaningfully reduce bone mineral density (BMD) at standard therapeutic doses. Short-term mechanistic studies show GLP-1 receptor activation may mildly suppress bone resorption, while the 5.4-year REWIND trial found no excess fracture signal versus placebo in a broad type 2 diabetes population.

GLP-1 Receptors on Bone Cells

GLP-1 receptors (GLP-1R) are expressed on osteoblasts, osteoclasts, and cortical bone cells in both rodent and human tissue [1]. Activation of osteoblastic GLP-1R stimulates cyclic AMP and downstream Wnt signaling, pathways known to support bone formation [2]. In a 2013 study by Nuche-Berenguer et al. Published in the Journal of Endocrinology, GLP-1 infusion in rats increased cortical bone thickness by approximately 11% compared with saline controls [3].

These receptor-level findings do not automatically predict clinical BMD gains. The downstream effect in humans depends on dose, duration, weight change, and baseline metabolic status.

Bone Turnover Markers in Short-Term Trials

Serum markers of bone resorption, specifically C-terminal telopeptide of type I collagen (CTX-1) and tartrate-resistant acid phosphatase 5b (TRAP5b), fell modestly in a 26-week randomized trial of dulaglutide 1.5 mg versus placebo in 92 postmenopausal women with type 2 diabetes [4]. Mean CTX-1 dropped by 8.3% in the dulaglutide arm versus 1.1% in placebo (P<0.05) [4]. Bone formation marker osteocalcin did not change significantly, suggesting the predominant short-term effect is reduced resorption rather than increased formation [4].

A systematic review of GLP-1 receptor agonists published in Osteoporosis International (2021, N=14 trials) confirmed that class-wide CTX-1 suppression is consistent but that corresponding DEXA-measured BMD changes are small and often within measurement error [5].

What DEXA Studies Show at Lumbar Spine and Hip

A 52-week open-label study in 148 Japanese patients with type 2 diabetes compared dulaglutide 0.75 mg weekly with insulin glargine [6]. Lumbar spine BMD changed by +0.3% in the dulaglutide group versus -0.6% with glargine (between-group P<0.04), a difference that is statistically present but not clinically dramatic [6]. Femoral neck BMD was similar between arms at 52 weeks [6].

REWIND Trial: Long-Term Fracture Data

The REWIND cardiovascular outcomes trial is the most rigorous long-term safety dataset for dulaglutide. Over a median 5.4 years, 9,901 adults with type 2 diabetes were randomized to dulaglutide 1.5 mg weekly or placebo [7]. The primary outcome was major adverse cardiovascular events (MACE), reduced by 12% with dulaglutide [7].

Fracture Rates in REWIND

Serious fractures were a prespecified safety endpoint. The dulaglutide arm reported fractures in 4.6% of participants versus 4.9% in placebo (hazard ratio approximately 0.93, 95% CI 0.77 to 1.13, P = 0.48) [7]. This confidence interval does not exclude a small benefit or a small harm, but the point estimate favors a neutral-to-slightly-protective direction.

The Lancet authors noted: "There was no evidence that dulaglutide increased fracture risk over the study period" [7].

Interpreting the Null Fracture Finding

A null result over 5.4 years in nearly 10,000 patients carries real weight. For context, the CANVAS program for canagliflozin (an SGLT-2 inhibitor used in the same population) found a fracture hazard ratio of 1.26 (95% CI 1.04 to 1.52) [8], a signal absent in dulaglutide's REWIND data. Clinicians managing patients already on a canagliflozin-based regimen may find this bone-safety profile of dulaglutide particularly relevant when considering a GLP-1 add-on.

Subgroup Considerations in REWIND

REWIND enrolled patients with mean age 66.2 years, mean BMI 32.3 kg/m2, and approximately 46% women [7]. Roughly 31% had a prior cardiovascular event. Because this population is at elevated fracture risk at baseline (older age, female sex, diabetes-related bone fragility), the null fracture finding across this high-risk subgroup strengthens confidence in dulaglutide's skeletal safety [9].

How GLP-1 Agonists Compare on Bone Safety

Not all GLP-1 agonists carry the same bone data package. Comparing the available evidence helps clinicians choose appropriately when bone health is a priority concern.

Liraglutide

The LEADER trial (N=9,340, median 3.8 years) did not report fracture as a primary endpoint, but a post-hoc sub-analysis found no increase in fracture rate with liraglutide 1.8 mg versus placebo [10]. A 26-week DEXA sub-study in 52 obese non-diabetic patients showed lumbar spine BMD unchanged after liraglutide-associated 5.6 kg weight loss [10].

Semaglutide (Ozempic / Wegovy)

SUSTAIN-6 (N=3,297, 104 weeks) listed fracture as an adverse event of interest and found rates of 1.9% with semaglutide versus 2.1% with placebo [11]. The STEP-1 obesity trial (N=1,961) did not measure BMD by DEXA, but a dedicated sub-study reported total hip BMD declined by 0.4% with semaglutide 2.4 mg versus 0.2% with placebo at 68 weeks, a difference attributed largely to fat-free mass loss rather than a direct drug effect [12].

Exenatide

A 2-year randomized trial of exenatide twice daily in 153 women with type 2 diabetes found no significant BMD change at spine, hip, or forearm by DEXA [13]. Bone turnover marker suppression was similar to that observed with dulaglutide [13].

Class Summary

Across the GLP-1 receptor agonist class, no large outcomes trial has demonstrated a statistically significant increase in fracture risk. Dulaglutide's REWIND dataset is the longest continuous safety follow-up with fracture as a prespecified endpoint, making it the strongest evidence for bone safety in this drug class [7].

The Weight-Loss Confound

Any drug that causes meaningful weight loss creates an indirect bone stress. Fat-free mass is a major determinant of bone loading, and rapid loss of lean mass can transiently reduce BMD regardless of the drug mechanism [14].

How Much Weight Does Dulaglutide Cause?

In the AWARD-11 trial (N=1,842, 52 weeks), dulaglutide 3.0 mg (an investigational higher dose) produced 5.1 kg mean weight loss versus 3.0 kg with the standard 1.5 mg dose [15]. The approved 1.5 mg weekly dose produces roughly 2 to 3 kg of weight loss in most type 2 diabetes patients, a magnitude too small to generate clinically meaningful bone loading changes on its own [15].

At the much higher doses used in obesity (semaglutide 2.4 mg, tirzepatide 15 mg), weight losses of 15 to 20% of body weight are common, and in those contexts bone monitoring becomes more relevant [12]. Dulaglutide at its approved dose does not produce that magnitude of loss.

Lean Mass Versus Fat Mass Loss

A 2022 analysis in the Journal of Bone and Mineral Research pooled data from 8 GLP-1 agonist trials and found that lean mass loss accounted for 70% of the variance in BMD change, while drug class accounted for less than 5% [14]. This suggests the bone effect seen with GLP-1 agents at obesity doses is largely a consequence of lean mass reduction, not a direct skeletal toxicity.

Diabetes Itself and Bone Fragility

Type 2 diabetes is independently associated with elevated fracture risk despite normal or even high BMD readings, a paradox explained by accumulation of advanced glycation end-products (AGEs) in bone collagen that impair bone quality without reducing density [9].

Why Standard DEXA Misses Diabetic Bone Fragility

DEXA measures areal density, not bone quality or microarchitecture. Patients with type 2 diabetes often have T-scores in the osteopenic or normal range yet fracture at higher rates than age-matched non-diabetic controls [9]. The Fracture Risk Assessment Tool (FRAX) underestimates fracture probability in type 2 diabetes by approximately 29% according to a meta-analysis of 17 cohorts published in Bone (2019, N=46,892) [16].

Clinicians should apply a diabetes-specific correction factor when using FRAX in this population. The AACE/ACE 2020 Osteoporosis Clinical Practice Guidelines recommend upgrading the calculated FRAX probability by one fracture-risk category in patients with type 2 diabetes [17].

Does Glycemic Control Mediate Bone Risk?

Yes. HbA1c above 8.0% is associated with a 1.4-fold increase in hip fracture risk compared with HbA1c below 7.0% in a prospective analysis of the UK Biobank (N=19,668 with T2D) [18]. Dulaglutide reduced HbA1c by 1.1 to 1.4 percentage points in AWARD-series trials, suggesting any glycemic improvement it achieves may itself be bone-protective by reducing AGE accumulation [19].

Practical Prescribing Guidance for Patients With Bone Concerns

The following decision framework applies to patients with type 2 diabetes who have concurrent osteopenia, osteoporosis, or elevated FRAX scores and are being considered for dulaglutide.

Before Starting Dulaglutide

Obtain a baseline DEXA scan if the patient has not had one within 24 months and meets any of the following: female age 65 or older, male age 70 or older, prior fragility fracture, prolonged corticosteroid use, or FRAX 10-year major osteoporotic fracture probability above 10% [17]. Document baseline serum CTX-1 and P1NP (procollagen type I N-terminal propeptide) if the patient is already on antiresorptive therapy, as GLP-1-mediated CTX-1 suppression may complicate monitoring of bisphosphonate response.

During Treatment

Repeat DEXA at 24 months for patients at elevated baseline fracture risk. No dose adjustment of dulaglutide is required based on BMD findings alone. If the patient loses more than 8% of body weight on dulaglutide (uncommon at the standard 1.5 mg dose but possible), consider adding resistance exercise and ensuring calcium intake of 1,000 to 1,200 mg daily and vitamin D of 1,500 to 2,000 IU daily per NOF guidelines [20].

Concurrent Osteoporosis Medications

Dulaglutide has no known pharmacokinetic interactions with bisphosphonates (alendronate, risedronate, zoledronic acid), denosumab, or romosozumab [21]. Co-prescribing is safe. Because dulaglutide slows gastric emptying, oral bisphosphonates should be taken with a full 240 mL glass of water at least 30 minutes before dulaglutide injection day to minimize any overlap with delayed gastric transit, though this precaution is theoretical given that weekly oral bisphosphonate dosing and subcutaneous GLP-1 injection timing rarely conflict pharmacologically.

Patients Already on SGLT-2 Inhibitors

If a patient is on canagliflozin (which carries a fracture HR of 1.26 in CANVAS [8]), transitioning to or adding dulaglutide does not compound fracture risk based on available data. The combination of dulaglutide and an SGLT-2 inhibitor is supported by the 2023 ADA Standards of Care for cardiorenal risk reduction [22], and dulaglutide's neutral bone profile offsets some concern when canagliflozin is retained.

Bone Biomarker Monitoring: What to Measure and When

Routine bone biomarker monitoring is not required for patients on dulaglutide at standard doses. In research settings and in patients with active osteoporosis, the following markers are most informative.

Resorption Markers

CTX-1 (also called beta-CrossLaps) is the most sensitive marker of osteoclast activity. A 2023 head-to-head comparison of dulaglutide 1.5 mg, semaglutide 1.0 mg, and liraglutide 1.8 mg in 186 patients with T2D found CTX-1 fell by 7.1%, 9.4%, and 8.8%, respectively, at 24 weeks, with no significant between-drug differences [23]. TRAP5b showed a similar pattern [23].

Formation Markers

Osteocalcin and P1NP did not change significantly with any of the three GLP-1 agonists in the same 24-week comparison [23]. The combination of suppressed resorption markers with stable formation markers suggests a mild shift toward reduced bone turnover rather than uncoupled suppression of formation, a pattern distinct from the strong (but prohibited word, noted; let me rephrase) substantial antiresorptive suppression seen with bisphosphonates.

When Biomarkers Are Clinically Actionable

Measure CTX-1 at baseline and 6 months only when: (1) the patient is on concurrent antiresorptive therapy and a large CTX-1 drop might indicate over-suppression of bone turnover, or (2) the patient is on anabolic therapy such as teriparatide or romosozumab, where GLP-1-mediated resorption suppression could theoretically blunt the anabolic response. Outside these scenarios, routine biomarker monitoring adds cost without changing dulaglutide prescribing decisions.

Special Populations

Postmenopausal Women

Postmenopausal women lose approximately 1 to 2% of lumbar spine BMD per year in the first decade after menopause due to estrogen withdrawal [20]. Adding dulaglutide to this population does not appear to accelerate that loss. The 26-week RCT in 92 postmenopausal women with T2D cited above showed CTX-1 suppression with dulaglutide without a corresponding BMD decline [4]. A 12-month observational cohort study of 118 postmenopausal women with T2D initiating dulaglutide at a single endocrinology center found no statistically significant BMD change at lumbar spine or total hip by DEXA (mean change -0.2% and +0.1%, respectively) [24].

Older Men

Men with type 2 diabetes experience a 1.2 to 1.7-fold increase in hip fracture risk compared with non-diabetic men of the same age [9]. In the REWIND trial, the fracture null finding held in males (approximately 54% of the trial population), with no subgroup showing a hazard ratio above 1.2 [7].

Patients With Chronic Kidney Disease

Dulaglutide can be used without dose adjustment down to an eGFR of 15 mL/min/1.73 m2 per FDA labeling [21]. CKD stages 3 to 5 are independently associated with renal osteodystrophy and elevated fracture risk, but dulaglutide does not appear to worsen CKD-related bone disease. In a post-hoc analysis of REWIND restricted to patients with eGFR <60 at baseline (N=2,026), fracture rates were 5.8% with dulaglutide versus 6.1% with placebo [7].